AiCure
AiCure, founded in 2010, is a New York-based healthcare technology company specializing in AI-driven medication adherence and clinical trial participation verification.
Profile
AiCure uses AI to verify medication adherence and monitor clinical trial participants via smartphone.
AiCure, founded in 2010, is a New York-based healthcare technology company specializing in AI-driven medication adherence and clinical trial participation verification. The company's flagship product, H.Code, is an AI-powered platform that uses computer vision, predictive analytics, and synchronous chat to monitor and assist trial participants via smartphone. AiCure has positioned itself as a leader in verified medical adherence, with its technology trusted by pharmaceutical companies, contract research organizations (CROs), and healthcare providers.
The platform has captured over 1.5 million participant doses across 46 countries and 45 languages, with a reported 92% participant retention rate. AiCure serves seven of the top ten global pharmaceutical companies and has deployed its technology in over 2,200 clinical trial sites. The company holds 84 patents, reflecting its focus on innovation in AI and healthcare. Recent industry trends, including the 2025-2026 tech layoffs and increased AI adoption in healthcare, suggest both opportunities and challenges for AiCure as it scales its platform and navigates a competitive landscape.
Who buys this
- Pharmaceutical companies
- Contract research organizations (CROs)
- Healthcare providers
- Clinical trial sites
- Biotechnology firms
Publicly disclosed clients
- Cerevel Therapeutics
- Sage Therapeutics
- Abbvie
Strengths and what to watch
Strengths
- Proven track record with 92% participant retention in clinical trials
- Extensive patent portfolio with 84 awarded patents
- Strong adoption by top pharmaceutical companies, including seven of the top ten globally
Watch for
- Potential regulatory scrutiny over AI-driven patient monitoring and data privacy
- Dependence on clinical trial budgets, which can fluctuate with economic conditions
- Competition from other AI-powered adherence and clinical trial monitoring platforms
Key Information
- Founded
- 2010
- Headquarters
- New York
Frequently Asked Questions
What does AiCure do?
AiCure uses AI and smartphone technology to verify medication adherence and monitor clinical trial participants. Their H.Code platform combines computer vision, predictive analytics, and chat to track patient compliance, serving pharmaceutical companies and research organizations with 92% participant retention across global trials.
How does AiCure's technology work for medication adherence?
AiCure's H.Code platform uses smartphone cameras and AI to visually confirm medication ingestion. Computer vision analyzes pill-taking behavior while synchronous chat provides real-time support, achieving 1.5 million verified doses across 46 countries with 84 patented technologies ensuring accuracy.
Which major companies use AiCure for clinical trials?
AiCure serves seven of the top ten global pharmaceutical firms, including Cerevel Therapeutics, Sage Therapeutics, and Abbvie. Their technology is deployed in over 2,200 clinical trial sites, demonstrating trust among leading drug developers and research organizations.
What makes AiCure different from other adherence monitoring solutions?
AiCure combines AI-powered visual verification with predictive analytics, distinguishing it from passive tracking methods. With 84 patents and 92% retention rates, their platform actively engages participants via smartphone, addressing both adherence and data quality challenges in decentralized trials.
Is AiCure's technology compliant with clinical trial regulations?
AiCure operates within FDA and global clinical trial frameworks, with its 84 patents including compliance features. However, as AI monitoring evolves, regulatory scrutiny around data privacy and algorithm transparency may impact deployment requirements for pharmaceutical partners.
How reliable is AiCure's smartphone-based monitoring?
AiCure reports 1.5 million successfully monitored doses with 92% participant retention, validated across 45 languages. Their computer vision and chat support maintain engagement while reducing site visits, though effectiveness depends on consistent smartphone access among trial populations.
Sources
- aicure.com — H.Code product description
- aicure.com — Company background and investor information
- www.bloomberg.com — Context on tech layoffs and AI industry trends
- aicure.com — Patient Connect product description